Purpose: We sought to identify clinical and demographic characteristics associated with treatment response and satisfaction in women undergoing onabotulinumtoxinA and sacral neuromodulation therapies. Materials and Methods: We analyzed data from the ROSETTA (Refractory Overactive Bladder: Sacral NEuromodulation versus BoTulinum Toxin Assessment) trial. Baseline participant characteristics and clinical variables were associated with 2 definitions of treatment response, including 1) a reduction in mean daily urgency incontinence episodes during 6 months and 2) a 50% or greater decrease in urgency incontinence episodes across 6 months. The OAB-S (Overactive Bladder-Satisfaction) questionnaire was used to assess satisfaction. Results: A greater reduction in mean daily urgency incontinence episodes was associated with higher HUI-3 (Health Utility Index-3) scores in the onabotulinumtoxinA group and higher baseline incontinence episodes (each p <0.001) in the 2 groups. Increased age was associated with a lesser decrease in incontinence episodes in the 2 groups (p <0.001). Increasing body mass index (adjusted OR 0.82/5 points, 95% CI 0.70e0.96) was associated with reduced achievement of a 50% or greater decrease in incontinence episodes after each treatment. Greater age (adjusted OR 0.44/10 years, 95% CI 0.30e0.65) and a higher functional comorbidity index (adjusted OR 0.84/1 point, 95% CI 0.71e0.99) were associated Accepted for publication April 27, 2017. No direct or indirect commercial incentive associated with publishing this article. The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number.
with reduced achievement of a 50% or greater decrease in urgency incontinence episodes in the onabotulinumtoxinA group only (p <0.001 and 0.041, respectively). In the onabotulinumtoxinA group increased satisfaction was noted with higher HUI-3 score (p ¼ 0.002) but there was less satisfaction with higher age (p ¼ 0.001). Conclusions: Older women with multiple comorbidities, and decreased functional and health related quality of life had decreased treatment response and satisfaction with onabotulinumtoxinA compared to sacral neuromodulation for refractory urgency incontinence.
Key Words: urinary bladder; urinary incontinence, urge; onabotulinumtoxinA; quality of life WOMEN with UUI refractory to primary treatment approaches, including medications and behavioral therapy, may be offered third line treatment options such as posterior tibial nerve stimulation, SNM or onabotulinumtoxinA. Understanding patient clinical and demographic characteristics potentially associated with the third line treatment response, especially in the setting of more invasive treatment approaches such as SNM and onabotulinumtoxinA, is important and may help optimize treatment success.
The ROSETTA trial was an open label, randomized trial in women with idiopathic refractory UUI who were randomized to onabotulinumtoxinA or SNM. 1 The objective of this planned secondary analysis was to identify baseline clinical and demographic factors associated with treatment response and satisfaction in women participating in this multicenter randomized trial.
MATERIALS AND METHODS
The design and primary results of the ROSETTA trial have been previously published. 1, 2 The institutional review board at each clinical site and coordinating center approved the protocol and participants provided written informed consent. Major inclusion criteria for women participating in the ROSETTA trial included a minimum of 6 UUIEs on a baseline 3-day bladder diary, not taking or stopping UUI medications at least 3 weeks prior to the baseline evaluation and urodynamic assessment within 18 months before randomization. Standardized demographic, clinical data and key procedural elements were collected at baseline.
Briefly, participants randomized to SNM underwent stage 1 lead placement by experienced surgeons in the operating suite. During the 7 to 14-day testing phase participants with 50% or greater improvement in mean UUIE on a 3-day bladder diary were categorized as clinical responders and were eligible for placement of the permanent implantable pulse generator. Those without this improvement had the lead removed. Participants randomized to onabotulinumtoxinA received a single cystoscopic intradetrusor injection of 200 U performed in clinic. Women with a 50% or greater reduction in UUIE on a bladder diary 1 month after injection were defined as onabotulinumtoxinA clinical responders.
Treatment response outcomes for this planned secondary analysis included 1) a reduction in mean daily UUIEs averaged across 6 months, 2) a 50% or greater decrease in UUIE on each completed diary across 6 months as recorded in monthly 3-day bladder diaries and 3) treatment satisfaction on OAB-SATq (Overactive Bladder Satisfaction with Treatment Questionnaire). 2 All participants with 1 to 6 post-baseline diaries were included in the mean daily UUIE analyses while only participants with at least 4 completed diaries were included in the 50% or greater decrease analyses. The potential variables thought to be associated with treatment response were sociodemographic characteristics, including age in years and race/ethnicity; medical history and functional status, including BMI as a continuous variable, smoking status, menopausal status, and the Timed Up and Go test; characteristics of urinary incontinence, including UUIE, Sandvik score and UDI-SF (Urogenital Distress Inventory-Short Form); symptom impact and incontinence related quality of life on OABq-SF) and IIQ-SF (Incontinence Impact QuestionnaireShort Form), and health related quality of life on HUI-3; and urodynamic variables and medical comorbidities, including history of recurrent urinary tract infections and FCI. 2, 3 To identify variables associated with a reduction in mean daily UUIEs during 1 to 6 months after treatment as a continuous outcome we fit linear mixed models for each potential predictor, controlling for treatment group, age group (less than 65 and 65 years or greater), site, month after treatment and interaction of treatment group with month. Person-month was used as the unit of analysis. Participants were treated as a random effect to account for the within subject correlation with time.
To evaluate whether the impact of the potential predictors differed by treatment group the models were fit with a treatment by predictor interaction term. To identify baseline variables associated with a 50% or greater reduction in UUIEs as a dichotomous outcome logistic regression models were fit for each potential predictor with all models controlling for treatment group and age group as factors included in the original randomization. An analogous linear model was used to examine the effect of predictors on treatment satisfaction using OAB-SATq at 6 months.
Initially each baseline variable was modeled individually to assess associations with each outcome. Parameter estimates, ORs and 95% CIs were generated by treatment group based on treatment stratified analyses. Variables in which the main effect or the interaction term was at p <0.10 using the Wald test were included as candidate terms in a combined multivariable model. That model then underwent backward variable selection so that each term in the final multivariable model was at p <0.10. Results were not adjusted for multiple comparisons and all p values should be interpreted accordingly. Analyses were performed with SASÒ, version 9.4.
RESULTS
A total of 190 participants randomized to onabotulinumtoxinA and 174 randomized to SNM were included in this secondary analysis. Baseline characteristics were similar in the treatment groups (supplementary The reduction in mean daily UUIEs during 6 months was not associated with most baseline covariates on univariable analysis. However, increasing age and higher (better) baseline OABq-SF QoL score were associated with a lesser decrease in mean daily UUIEs during 6 months (supplementary table 2, http://jurology.com/). Hispanic/Latina ethnicity, detrusor overactivity on cystometrogram, a greater number of daily UUIEs and total UIEs per day, higher (worse) OABq-SF symptom bother scores and higher (better) HUI-3 scores were associated with a greater reduction in mean daily UUIEs.
A greater effect was noted in the onabotulinumtoxinA group for UUIEs and total UIEs. Multivariable analyses revealed that age and greater baseline UUIE frequency in the onabotulinumtoxinA and SNM groups were associated with a UUIE reduction (table 1). For age there was an average decrease in reduction of about 0.3 UUIEs per day for each added decade of age. For greater baseline UUIE frequency there was an increased reduction of 0.6 UUIEs per day for each unit increase in baseline UUIEs, ie an increased reduction of approximately 60% of the incremental level. Increasing age was associated with a lower treatment response while higher frequency of baseline UUIEs was associated with an increased treatment response. Higher HUI-3 score was also associated with an improved treatment response with some evidence of a greater reduction in UUIEs in the onabotulinumtoxinA group.
Similarly univariable analysis of the achievement of a 50% or greater reduction in UUIEs revealed that increased age, higher BMI, higher (worse) FCI score, higher (worse) baseline IIQ-SF score and higher (worse) Sandvik score were associated with decreased odds (supplementary table 3 , http://jurology.com/). Greater volume at maximum cystometric capacity and higher (better) HUI-3 score were associated with increased odds of achieving a 50% or greater reduction in UUIEs. A greater effect (lower OR) was noted in the onabotulinumtoxinA group for FCI.
On multivariable analysis increasing age and higher BMI were associated with decreased odds of achieving a treatment response of a 50% or greater reduction in UUIEs with the effect of age greater in the onabotulinumtoxinA group (table 2). Higher FCI score was associated with decreased odds of achieving a 50% or greater reduction in UUIEs only in the onabotulinumtoxinA group.
Univariable analysis revealed that for each treatment greater age, UUIEs per day, total UIEs per day and Sandvik score were associated with decreased treatment satisfaction, as was Latina ethnicity (supplementary table 4, http://jurology. com/). African American race was associated with increased satisfaction relative to Caucasian race. Increased HUI-3 score was associated with increased satisfaction in the onabotulinumtoxinA group.
Multivariable analysis revealed that in each treatment group African American race was associated with increased satisfaction, and increased UUIEs per day and stress UIEs per day with 
DISCUSSION
In this planned secondary analysis of women with refractory UUI randomized to onabotulinumtoxinA or SNM increasing age was associated with a lesser mean reduction (less efficacy) while higher baseline HUI-3 score and UUIEs were associated with an increased mean reduction (greater efficacy) in UUIEs per day with the HUI-3 effect greater in the onabotulinumtoxinA group. Similarly regarding the outcome of a 50% or greater reduction in UUIEs increasing age and higher BMI were associated with decreased odds of a treatment response in all participants. A higher FCI score conferred decreased odds only in the onabotulinumtoxinA group. These 2 specific treatment outcomes were studied since they are commonly reported in the onabotulinumtoxinA and SNM literature. Overall treatment satisfaction with these third line therapies was associated with African American race and decreased satisfaction was associated with increased UUIEs and stress UIEs. Similar to treatment responsiveness increased age was associated with less satisfaction in the onabotulinumtoxinA group. Better health related QOL was associated with greater satisfaction with onabotulinumtoxinA therapy. Increasing age was independently associated with a poorer treatment response to each treatment and for each UUIE treatment response definition used in this study. The age association suggests that lower urinary tract changes which develop with aging, including decreased urethral closure pressure and detrusor contractility, and increased detrusor overactivity, may predispose older women to a UUI phenotype that may be more refractory to treatment. 4e6 To provide perspective on average a 55-year-old woman would have an increased mean reduction of 0.64 UUIEs per day compared to a 65-year-old woman. In the onabotulinumtoxinA group a 55-yearold woman would have about twice the odds of achieving a 50% or greater reduction in UUIEs compared to a 65-year-old woman. The effect of age in previous reports of SNM treatments has varied. Prior SNM studies described older women gaining benefit from SNM but showed higher continence rates and a greater UUIE reduction in the younger group. 7, 8 In contrast, Peters et al prospectively evaluated 328 patients, of whom 83% were women, and found that SNM success was not age dependent. 9 Including an urgency only population and pudendal neuromodulation may have affected the latter results.
Less information exists regarding the effect of age on onabotulinumtoxinA treatment response and satisfaction. One group reported results in 27 patients with refractory UUI after comparing outcomes in younger and older patients (mean age 55 AE 15 and 68 AE 13 years, respectively). 10 Although younger age predicted a 50% or greater UUIE reduction on univariate analysis, age was not significant on multivariable analysis. In the current study we found a differential treatment effect with respect to age and the 50% or greater UUIE reduction treatment outcome, which to our knowledge has not been reported previously. With increasing age women undergoing onabotulinumtoxinA treatment had a decreased treatment response compared to those undergoing SNM. This differential effect of treatment type was not noted for the outcome of reductions in mean daily incontinence episodes during 6 months with increasing age mitigating the response to each treatment.
In the current study we found that increased baseline BMI decreased the odds of achieving a 50% or greater UUIE reduction. For example, the model estimated that a woman with a BMI of 25 kg/m 2 would have about 50% greater odds of achieving a 50% or greater reduction in UUIEs than a woman with a BMI of 35 kg/m 2 . This is consistent with prior epidemiological literature in which increasing BMI was associated with UUI severity. 11, 12 Determining the association of BMI for predicting treatment success is important because it is a modifiable risk factor. Each 5-point increase in baseline BMI decreased the odds of attaining a 50% or greater UUIE reduction by approximately 20%. Alternatively a woman with a BMI of 25 kg/m 2 would have about 50% greater odds of achieving a 50% or greater reduction in UUIEs than a woman with a BMI of 35 kg/m 2 , assuming that all other covariates were the same. Subak et al found that weight loss after bariatric surgery was associated with substantially decreased urinary incontinence during 3 years. 13 Further research is needed of the role of weight loss in UUI refractory to treatment.
Other characteristics associated with treatment response included the baseline number of UUIEs per day and HUI-3 in the overall reduction in mean daily UUIEs. Women with higher baseline UUIEs per day experienced a greater mean decrease in UUIEs per day. This finding reinforces previous results, including those in a randomized trial of anticholinergic therapy vs onabotulinumtoxinA 14 and another describing the results of SNM testing. 15 HUI-3 is an instrument used to measure general health status and HRQoL which is scored on a scale of 0.00ddeath to 1.00dperfect health.
2 HUI-3 has been noted to provide valid measurements for utility scores in women with stress, urgency and mixed urinary incontinence. 16 In our study HUI-3 demonstrated responsiveness to a change in the treatment of refractory UUI in the onabotulinumtoxinA and SNM groups. Higher baseline HUI-3 scores were associated with a better treatment response. For example, a woman with a baseline HUI-3 score of 0.7 would experience an average reduction of 0.5 episodes per day more compared to a woman with a baseline score of 0.4. This represents a difference of 0.3 in HUI-3 score, which is approximately the baseline standard deviation in our study population and is 10 times the reported minimally important difference of 0.03. 17 Women with higher health related quality of life had a greater improvement in the mean daily reduction in UUIEs during 6 months in each treatment group with greater decrease in the onabotulinumtoxinA group. This may reflect a differential impact of incontinence on general health status and HRQoL, and a greater chance of treatment benefit. The trend toward a greater beneficial effect of a higher HUI-3 score on the success of onabotulinumtoxinA is unclear. Further research is again warranted to understand the particular interaction between botulinum toxin and health status.
Finally, with respect to FCI and its association with a 50% or greater reduction in UUIEs in the onabotulinumtoxinA group, women with more medical comorbidities have a greater likelihood of increased incontinence severity. 18, 19 In the current study a woman with a baseline FCI score of 1 would have approximately 70% greater odds of achieving a 50% or greater reduction in UUIEs than a woman with a baseline score of 4. Assessment of baseline physical function and HRQoL status as measured by FCI is important since it may be used to control for baseline comorbidity, provide a perspective on potential return to functional levels after treatment and serve as a predictor of outcome. 20 Incontinence treatment may be more difficult in women with more morbidities due to the potential cumulative negative impact on daily functioning and bladder control. This was previously noted in 105 men and women in whom decreased SNM cure rates were associated with having 3 or more chronic medical conditions regardless of age. 8 It is unclear why we found a differential treatment effect for onabotulinumtoxinA. As with HUI-3, further evaluation is needed to better understand this specific finding.
Our planned secondary analysis had several strengths. It allowed robust assessment of a large number of women who met standardized criteria for refractory UUI with clearly defined preoperative clinical and demographic variables, and validated outcome measures, treatment outcomes and satisfaction. Study limitations include a followup limited to 6 months and the inclusion of only women participants.
CONCLUSIONS
Older women with multiple comorbidities, and decreased functional and health related QoL had reduced treatment response and satisfaction with onabotulinumtoxinA compared to sacral neuromodulation for refractory urgency incontinence.
Increasing BMI was associated with a decreased response to each treatment. This information may help individualize treatment approaches for these more invasive third line therapies.
